Skip to main content
Article thumbnail
Location of Repository

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

By J. Kevin Hicks, Jeffrey R. Bishop, Katrin Sangkuhl, Daniel J Müller, Yuan Ji, Susan G. Leckband, J. Steven Leeder, Rebecca L. Graham, Dana L. Chiulli, Adrián LLerena, Todd C. Skaar, Stuart A. Scott, Julia C. Stingl, Teri E. Klein, Kelly E. Caudle and Andrea Gaedigk


Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at

Topics: SSRIs, Paroxetine, Fluoxetine, Fluvoxamine, Citalopram, Escitalopram, Sertraline, Pharmacogenomics, Personalized medicine, CPIC
Publisher: Wiley
Year: 2015
DOI identifier: 10.1002/cpt.147
OAI identifier:
Provided by: IUPUIScholarWorks

Suggested articles

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.